USE OF INTERLEUKIN-6 AND C-REACTIVE PROTEIN IN MULTIPLE-MYELOMA - FACTS, CONSIDERATIONS AND PERSPECTIVES

The experimental and clinical data collected over the last few years h ave stressed the importance of Interleukin-6 and C-Reactive protein as promising markers in Multiple Myeloma management. However, various no n-specific conditions have shown to markedly influence these parameter s, limiting their potential role as markers discriminating between ben ign and malignant monoclonal gammopathies. In the light of our experie nce a cautious use of these parameters is recommended, before their ro utinely utilization in the clinical practice.